Relapse after First-Line Fixed Duration Ibrutinib plus Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with up to 5 Years of Follow-up in the Phase 2 Captivate Study

被引：0

作者：

Ghia, Paolo ^{[1
,2
]}

Wierda, William G. ^{[3
]}

Barr, Paul M. ^{[4
]}

Kipps, Thomas J. ^{[5
]}

Siddiqi, Tanya ^{[6
]}

Allan, John N. ^{[7
]}

Hunter, Zoe ^{[8
]}

Zhou, Cathy ^{[8
]}

Szoke, Anita ^{[8
]}

Dean, James P. ^{[9
,10
]}

Tam, Constantine S. ^{[11
,12
]}

机构：

[1] Univ Vita Salute San Raffaele, Milan, Italy

[2] IRCCS Osped San Raffaele, Milan, Italy

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[4] Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY USA

[5] UC San Diego Moores Canc Ctr, Duarte, CA USA

[6] City Hope Natl Med Ctr, Duarte, CA USA

[7] Weill Cornell Med, Long Isl City, NY USA

[8] AbbVie, N Chicago, IL USA

[9] AbbVie, IMBRUVICA, N Chicago, IL USA

[10] AbbVie, Pediat Oncol, N Chicago, IL USA

[11] Alfred Hosp, Melbourne, Vic, Australia

[12] Monash Univ, Melbourne, Vic, Australia

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-187128

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[1] Outcomes in high-risk subgroups after fixed-duration ibrutinib plus venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study
Wierda, William G.
Jacobs, Ryan
Barr, Paul M.
Allan, John N.
Siddiqi, Tanya
Tedeschi, Alessandra
Kipps, Thomas J.
O'Brien, Susan Mary
Badoux, Xavier C.
Visentin, Andrea
Lasica, Masa
Carney, Dennis
Camburn, Anna Elinder
Torroba, Javier De la Serna
Szafer-Glusman, Edith
Zhou, Cathy
Szoke, Anita
Dean, James P.
Ghia, Paolo
Tam, Constantine S.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[2] Fixed-duration ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study
Burger, J. A.
Barr, P. M.
Allan, J. N.
Siddiqi, T.
Wierda, W. G.
Tam, C. S.
Moreno, C.
Tedeschi, A.
Szafer-Glusman, E.
Zhou, C.
Abbazio, C.
Dean, J. P.
Szoke, A.
Ghia, P.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 87 - 88
[3] Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study
Wierda, William G.
Jacobs, Ryan
Barr, Paul M.
Allan, John N.
Siddiqi, Tanya
Tedeschi, Alessandra
Kipps, Thomas J.
O'Brien, Susan M.
Badoux, Xavier C.
Visentin, Andrea
Lasica, Masa
Carney, Dennis
Camburn, Anna Elinder
De la Serna, Javier
Szafer-Glusman, Edith
Zhou, Cathy
Szoke, Anita
Dean, James P.
Ghia, Paolo
Tam, Constantine S.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S342 - S342
[4] Fixed-duration ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study.
Barr, Paul M.
Allan, John N.
Siddiqi, Tanya
Wierda, William G.
Tam, Constantine Si Lun
Moreno, Carolina D.
Tedeschi, Alessandra
Szafer-Glusman, Edith
Zhou, Cathy
Abbazio, Chris
Dean, James P.
Szoke, Anita
Ghia, Paolo
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[5] Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study
Tam, Constantine S.
Siddiqi, Tanya
Allan, John N.
Kipps, Thomas J.
Flinn, Ian W.
Kuss, Bryone J.
Opat, Stephen
Barr, Paul M.
Tedeschi, Alessandra
Jacobs, Ryan
Badoux, Xavier C.
Ghia, Paolo
Sukbuntherng, Juthamas
Salem, Ahmed Hamed
Russell, Kristin
Eckert, Karl
Zhou, Cathy
Ninomoto, Joi
James, Danelle F.
Wierda, William G.
BLOOD, 2019, 134
[6] Phase 2 CAPTIVATE Results of Ibrutinib Plus Venetoclax in First-Line Chronic Lymphocytic Leukemia
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (07) : 2 - 4
[7] Fixed-Duration First-Line Treatment With Ibrutinib Plus Venetoclax for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Primary Analysis of the Fixed-Duration Cohort of the Phase 2 CAPTIVATE Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (07) : 4 - 5
[8] THE PHASE 2 CAPTIVATE STUDY: PRIMARY ANALYSIS OF A FIXED-DURATION COHORT FOLLOWING FIRST-LINE TREATMENT WITH IBRUTINIB PLUS VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
Dela Rosa, Maria
Anderson, Blanche
Ninomoto, Joi
Krigsfeld, Gabe
Wierda, William
Siddiqi, Tanya
ONCOLOGY NURSING FORUM, 2022, 49 (02) : E55 - E56
[9] Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL).
Wierda, William G.
Siddiqi, Tanya
Flinn, Ian
Badoux, Xavier C.
Kipps, Thomas J.
Allan, John N.
Tedeschi, Alessandra
Pagel, John M.
Kuss, Bryone J.
Barca, Eva Gonzalez
Ghia, Paolo
Eckert, Karl
Zhou, Cathy
Ninomoto, Joi
Dean, James P.
James, Danelle Frances
Tam, Constantine
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[10] Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study
Moreno, Carol
Solman, Isabelle G.
Tam, Constantine S.
Grigg, Andrew
Scarfo, Lydia
Kipps, Thomas J.
Srinivasan, Srimathi
Mali, Raghuveer Singh
Zhou, Cathy
Dean, James P.
Szafer-Glusman, Edith
Choi, Michael
BLOOD ADVANCES, 2023, 7 (18) : 5294 - 5303

← 1 2 3 4 5 →